Top

BMC Immunology

Published in:

Open Access 01-12-2013 | Research article

DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice

Authors: Jun Cao, Yiqi Jin, Wei Li, Bin Zhang, Yang He, Hongqiang Liu, Ning Xia, Huafeng Wei, Jian Yan

Published in: BMC Immunology | Issue 1/2013

Abstract

Background

Although DNA vaccine holds a great potential for cancer immunotherapy, effective long-lasting antitumoral immunity sufficient to induce durable responses in cancer patients remains to be achieved. Considering the pivotal role of dendritic cells (DC) in the antigen processing and presentation, we prepared DC-targeting DNA vaccines by fusing tumor-associated antigen HER2/neu ectodomain to single chain antibody fragment (scFv) from NLDC-145 antibody specific for DC-restricted surface molecule DEC-205 (scFv^NLDC-145), and explored its antitumoral efficacy and underlying mechanisms in mouse breast cancer models.

Results

In vivo targeting assay demonstrated that scFv^NLDC-145 specifically delivered DNA vaccine-encoded antigen to DC. Compared with untargeted HER2/neu DNA vaccines, vaccination with scFv^NLDC-145-HER2/neu markedly promoted the HER2/neu-specific cellular and humoral immune responses with long-lasting immune memory, resulting in effective protection against challenge of HER2/neu-positive D2F2/E2 breast tumor while ineffective in parental HER2/neu-negative D2F2 breast tumor. More importantly, in combination with temporary depletion of regulatory T cells (Treg) by low-dose cyclophosphamide, vaccination with scFv^NLDC-145-HER2/neu induced the regression of established D2F2/E2 breast tumor and significantly retarded the development of spontaneous mammary carcinomas in transgenic BALB-neuT mice.

Conclusion

Our findings demonstrate that DC-targeted DNA vaccines for in vivo direct delivery of tumor antigens to DC could induce potent antigen-specific cellular and humoral immune responses and, if additional combination with systemic Treg depletion, was able to elicit an impressively therapeutic antitumoral activity, providing a rationale for further development of this approach for cancer treatment.

Available only for authorised users

Zheng C, Juhls C, Oswald D, Sack F, Westfehling I, Wittig B, Babiuk LA, Hurk SDL: Effect of different nuclear localization sequences on the immune responses induced by a MIDGE vector encoding bovine herpesvirus-1 glycoprotein D. Vaccine. 2006, 24: 4625-4629. 10.1016/j.vaccine.2005.08.046.CrossRefPubMed

Kutzler MA, Weiner DB: DNA vaccines: ready for prime time?. Nat Rev. 2008, 9: 776-788. 10.1038/nrg2432.CrossRef

Wolff JA, Malone R, Williams P, Chong W, Acsadi G, Jani A, Felgner P: Direct gene transfer into mouse muscle in vivo. Science. 1990, 247: 1465-1468. 10.1126/science.1690918.CrossRefPubMed

Casares S, Inaba K, Brumeanu T-D, Steinman RM, Bona CA: Antigen presentation by dendritic cells following immunization with DNA encoding a class II-restricted viral epitope. J Exp Med. 1997, 186: 1481-1486. 10.1084/jem.186.9.1481.PubMedCentralCrossRefPubMed

Porgador A, Irvine K, Iwasaki A, Barber B, Restifo N, Germain R: Predominant role for directly transfected dendritic cells in antigen presentation to CD8⁺ T cells after gene gun immunization. J Exp Med. 1998, 188: 1075-1082. 10.1084/jem.188.6.1075.PubMedCentralCrossRefPubMed

Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B: DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med. 1999, 189: 169-178. 10.1084/jem.189.1.169.PubMedCentralCrossRefPubMed

Lindquist RL, Shakhar G, Dudziak D, Wardemann H, Eisenreich T, Dustin ML, Nussenzweig MC: Visualizing dendritic cell networks in vivo. Nat Immunol. 2004, 5: 1243-1250. 10.1038/ni1139.CrossRefPubMed

Iwasaki A, Torres CAT, Ohashi PS, Robinson HL, Barber BH: The dominant role of bone marrow derived cells in CTL induction following plasmid DNA immunization at different sites. J Immunol. 1997, 159: 11-14.PubMed

Corr M, von Damm A, Lee DJ, Tighe H: In vivo priming by DNA injection occurs predominantly by antigen transfer. J Immunol. 1999, 163: 4721-4727.PubMed

10.

Nchinda G, Kuroiwa J, Oks M, Trumpfheller C, Park CG, Huang Y, Hannaman D, Schlesinger SJ, Mizenina O, Nussenzweig MC, Uberla K, Steinman RM: The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest. 2008, 118: 1427-1436. 10.1172/JCI34224.PubMedCentralCrossRefPubMed

11.

Tacken P, de Vries I, Torensma R, Figdor C: Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol. 2007, 7: 790-802. 10.1038/nri2173.CrossRefPubMed

12.

Carayanniotis G, Barber BH: Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC. Nature. 1987, 327: 59-61. 10.1038/327059a0.CrossRefPubMed

13.

Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM: In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004, 199: 815-824. 10.1084/jem.20032220.PubMedCentralCrossRefPubMed

14.

Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y: Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice. Clin Cancer Res. 2009, 15: 4612-4621. 10.1158/1078-0432.CCR-08-3321.CrossRefPubMed

15.

Carter RW, Thompson C, Reid DM, Wong SY, Tough DF: Preferential induction of CD4⁺ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. J Immunol. 2006, 177: 2276-2284.CrossRefPubMed

16.

He LZ, Crocker A, Lee J, Mendoza-Ramirez J, Wang XT, Vitale LA, O’Neill T, Petromilli C, Zhang HF, Lopez J, Rohrer D, Keler T, Clynes R: Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol. 2007, 178: 6259-6267.CrossRefPubMed

17.

Tagliani E, Guermonprez P, Sepúlveda J, Lopez Bravo M, Ardavin C, Amigorena S, Benvenuti F, Burrone OR: Selection of an antibody library identifies a pathway to induce immunity by targeting CD36 on steady-state CD8 alpha⁺ dendritic cells. J Immunol. 2008, 180: 3201-3209.CrossRefPubMed

18.

Ramakrishna V, Treml JF, Vitale L, Connolly JE, O’Neill T, Smith P, Jones CL, He L, Goldstein J, Wallace PK, Keler T, Endres MJ: Mannose receptor targeting of tumor antigen pme117 to human dendritic cells directs antimelanoma T cell responses via multiple HLA molecules. J Immunol. 2004, 172: 2845-2852.CrossRefPubMed

19.

Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, Figdor CG: Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood. 2005, 106: 1278-1285. 10.1182/blood-2005-01-0318.CrossRefPubMed

20.

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989, 244: 707-712. 10.1126/science.2470152.CrossRefPubMed

21.

Klapper LN, Kirschbaum MH, Sela M, Yarden Y: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res. 2000, 77: 25-79.CrossRefPubMed

22.

Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, RB L- s, Moe R, Cheever MA: Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 1994, 54: 16-20.PubMed

23.

Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA: High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol. 1997, 15: 3363-3367.PubMed

24.

Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 2002, 20: 2624-2632. 10.1200/JCO.2002.06.171.CrossRefPubMed

25.

Knutson KL, Schiffman K, Cheever MA, Disis ML: Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p 369–377, results in short-lived peptide-specific immunity. Clin Cancer Res. 2002, 8: 1014-1018.PubMed

26.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed

27.

Foy TM, Bannink J, Sutherland RA, McNeill PD, Moulton GG, Smith J, Cheever MA, Grabstein K: Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor. Vaccine. 2001, 19: 2598-2606. 10.1016/S0264-410X(00)00493-X.CrossRefPubMed

28.

Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, Forni G: Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med. 1998, 188: 589-596. 10.1084/jem.188.3.589.PubMedCentralCrossRefPubMed

29.

Demangel C, Zhou J, Choo AB, Shoebridge G, Halliday GM, Britton WJ: Single chain antibody fragments for the selective targeting of antigens to dendritic cells. Mol Immunol. 2005, 42: 979-985. 10.1016/j.molimm.2004.09.034.CrossRefPubMed

30.

Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F: Electroporated DNA vaccine clears away multifocal mammary carcinomas in HER-2/neu transgenic mice. Cancer Res. 2004, 64: 2858-2864. 10.1158/0008-5472.CAN-03-2962.CrossRefPubMed

31.

Wei H, Wang H, Lu B, Li B, Hou S, Qian W, Fan K, Dai J, Zhao J, Guo Y: Cancer immunotherapy using in vitro genetically modified targeted dendritic cells. Cancer Res. 2008, 68: 3854-3862. 10.1158/0008-5472.CAN-07-6051.CrossRefPubMed

32.

Ulmer JB, Wahren B, Liu MA: Gene-based vaccines: recent technical and clinical advances. Trends Mol Med. 2006, 12: 216-222. 10.1016/j.molmed.2006.03.007.CrossRefPubMed

33.

Swee LK, Guimaraes CP, Sehrawat S, Spooner E, Barrasa MI, Ploegh HL: Sortase-mediated modification of αDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes. Proc Natl Acad Sci U S A. 2013, 110: 1428-1433. 10.1073/pnas.1214994110.PubMedCentralCrossRefPubMed

34.

Pilon SA, Piechocki MP, Wei WZ: Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol. 2001, 167: 3201-3206.CrossRefPubMed

35.

Sloots A, Mastini C, Rohrbach F, Weth R, Curcio C, Burkhardt U, Jäger E, Forni G, Cavallo F, Wels WS: DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma. Clin Cancer Res. 2008, 14: 6933-6943. 10.1158/1078-0432.CCR-08-1257.CrossRefPubMed

36.

Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, Khleif SN: Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol. 2011, 41: 2977-2986. 10.1002/eji.201141639.CrossRefPubMed

37.

Matar P, Rozados VR, Gervasoni SI, Scharovsky OG: Th2/Th1 switch induced by a single low-dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother. 2002, 50: 588-596. 10.1007/s00262-001-0237-3.CrossRefPubMed

38.

Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlei D, Belardelli F: Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest. 1998, 101: 429-441. 10.1172/JCI1348.PubMedCentralCrossRefPubMed

39.

Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF: Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol. 2005, 174: 4465-4469.CrossRefPubMed

40.

Liu P, Jaffar J, Hellstrom I, Hellstrom KE: Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J Immunother. 2010, 33: 53-59. 10.1097/CJI.0b013e3181b56af4.PubMedCentralCrossRefPubMed

41.

Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM: Recruitment of latent pools of high-avidity CD8 (+) T cells to the antitumor immune response. J Exp Med. 2005, 201: 1591-1602. 10.1084/jem.20042167.PubMedCentralCrossRefPubMed

42.

Ambrosino E, Spadaro M, Iezzi M, Curcio C, Forni G, Musiani P, Wei WZ, Cavallo F: Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res. 2006, 66: 7734-7740. 10.1158/0008-5472.CAN-06-1432.CrossRefPubMed

43.

Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E: Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res. 2007, 67: 1326-1334. 10.1158/0008-5472.CAN-06-3290.PubMedCentralCrossRefPubMed

44.

Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, Lu Y, Miyagishi M, Kodama T, Honda K, Ohba Y, Taniguchi T: DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature. 2007, 448: 501-505. 10.1038/nature06013.CrossRefPubMed

45.

Granelli-Piperno A, Shimeliovich I, Pack M, Trumpfheller C, Steinman RM: Dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin/CD209 is abundant on macrophages in the normal human lymph node and is not required for dendritic cell stimulation of the mixed leukocyte reaction. J Immunol. 2005, 175: 4265-4273.PubMedCentralCrossRefPubMed

46.

Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G: Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2012, 1: 1111-1134. 10.4161/onci.21494.PubMedCentralCrossRefPubMed

Title: DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice
Authors: Jun Cao
Yiqi Jin
Wei Li
Bin Zhang
Yang He
Hongqiang Liu
Ning Xia
Huafeng Wei
Jian Yan
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: BMC Immunology / Issue 1/2013
Electronic ISSN: 1471-2172
DOI: https://doi.org/10.1186/1471-2172-14-39

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice

Abstract

Background

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2013

Impact of hepatitis C virus co-infection on HIV patients before and after highly active antiretroviral therapy: an immunological and clinical chemistry observation, Addis Ababa, Ethiopia

Local and systemic neutrophilic inflammation in patients with lung cancer and chronic obstructive pulmonary disease

A comparison of sex-specific immune signatures in Gulf War illness and chronic fatigue syndrome

Expression of Toll-like receptors 2 and 9 in cells of dog jejunum and colon naturally infected with Leishmania infantum

Injury-elicited stressors alter endogenous retrovirus expression in lymphocytes depending on cell type and source lymphoid organ

Glomerular C1q deposition and serum anti-C1q antibodies in anti-glomerular basement membrane disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page